# Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:

> **NCT04175522** · PHASE2 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 23 (actual)

## Conditions studied

- Autoimmune Encephalitis

## Interventions

- **DRUG:** Immunoglobulin G

## Key facts

- **NCT ID:** NCT04175522
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-20
- **Primary completion:** 2020-06-11
- **Final completion:** 2020-06-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04175522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04175522, "Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04175522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*